45:12-9.11

LEGISLATIVE HISTORY CHECKLIST

Compiled by the NJ State Law Library

LAWS OF: 2015 **CHAPTER**: 65

NJSA: 45:12-9.11 (Authorizes optometrists to continue prescribing medications containing

hydrocodone)

BILL NO: S2578 (Substituted for A3922)

SPONSOR(S) Gill and others

DATE INTRODUCED: December 1, 2014

COMMITTEE: ASSEMBLY: Regulated Professions

SENATE: Commerce

AMENDED DURING PASSAGE: No

DATE OF PASSAGE: ASSEMBLY: May 14, 2015

SENATE: December 18, 2014

DATE OF APPROVAL: June 26, 2015

FOLLOWING ARE ATTACHED IF AVAILABLE:

FINAL TEXT OF BILL (Introduced version of bill enacted)

S2578

SPONSOR'S STATEMENT: (Begins on page 2 of introduced bill)

Yes

COMMITTEE STATEMENT: ASSEMBLY: Yes

SENATE: Yes

(Audio archived recordings of the committee meetings, corresponding to the date of the committee statement, *may possibly* be found at www.njleg.state.nj.us)

FLOOR AMENDMENT STATEMENT: No

LEGISLATIVE FISCAL ESTIMATE: No

A3922

SPONSOR'S STATEMENT: (Begins on page 2 of introduced bill)

Yes

COMMITTEE STATEMENT: ASSEMBLY: Yes

SENATE: No

FLOOR AMENDMENT STATEMENT: No

LEGISLATIVE FISCAL ESTIMATE: No

(continued)

V	ETO MESSAGE:	No
G	OVERNOR'S PRESS RELEASE ON SIGNING:	No
To	ING WERE PRINTED: To check for circulating copies, contact New Jersey State Government Tublications at the State Library (609) 278-2640 ext.103 or mailto:refdesk@njstatelil	o.org
R	EPORTS:	No
Н	EARINGS:	No
N	IEWSPAPER ARTICLES:	No
LAW/RWH		

P.L.2015, CHAPTER 65, *approved June 26, 2015* Senate, No. 2578

1	AN ACT concerning optometrist prescribing authority and amending
2	P.L.1991, c.385.
3	
4	BE IT ENACTED by the Senate and General Assembly of the State
5	of New Jersey:
6	
7	1. Section 9 of P.L.1991, c.385 (C.45:12-9.11) is amended to
8	read as follows:
9	9. a. Whenever in any law there is a requirement or duty with
10	respect to the prescription, administration or dispensing of any drug
11	which applies to any person authorized to prescribe that drug, the
12	same shall apply to an optometrist when prescribing, administering
13	or dispensing a pharmaceutical agent pursuant to R.S.45:12-1,
14	except that an optometrist shall not dispense a prescription as
15	provided for in R.S.45:12-1 in an amount exceeding a 72-hour
16	supply of that prescription unless the prescription is dispensed at no
17	charge to the patient. Subject to the provisions of P.L.1991, c.385
18	(C.45:12-9.8 et seq.), an optometrist authorized to prescribe,
19	administer, or dispense a pharmaceutical agent shall be permitted to
20	prescribe, administer, and dispense for the purpose of diagnosing
21	and treating deficiencies, deformities, diseases, or abnormalities of
22	the human eye and adnexae pharmaceutical agents classified as
23	Schedule III, IV, and V controlled dangerous substances and,
24	regardless of schedule, pharmaceutical agents containing
25	hydrocodone.
26	b. Notwithstanding the provisions of subsection a. of this
27	section, an optometrist may dispense a pharmaceutical agent, as
28	provided for in R.S.45:12-1, that is delivered to the eye through a
29	contact lens and may dispense such pharmaceutical agent at a
30	charge to the patient.
31	(cf: P.L.2010, c.12, s.2)
32	
33	2. This act shall take effect immediately.
34	
35	
36	STATEMENT
37	
38	This bill codifies current regulations concerning optometrist
39	prescribing authority, including permitting optometrists to

 $\textbf{EXPLANATION-Matter enclosed in bold-faced brackets \cite{law} in the above bill is not enacted and is intended to be omitted in the law.}$

prescribe, administer, and dispense pharmaceutical agents

containing hydrocodone.

40

S2578

Under N.J.A.C.13:38-2.4, optometrists certified to prescribe pharmaceutical agents are permitted to prescribe Schedule III, IV, and V controlled dangerous substances. Pursuant to this authority, optometrists have for many years prescribed products containing hydrocodone, formerly a Schedule III controlled dangerous substance, without incident.

Effective October 6, 2014, the Drug Enforcement Administration in the U.S. Department of Justice rescheduled products containing hydrocodone from Schedule III to Schedule II, meaning that optometrists are no longer authorized to prescribe such products under State law. This bill provides that, notwithstanding the federal rescheduling of hydrocodone, optometrists will be permitted to continue prescribing pharmaceutical agents containing hydrocodone as they have historically done. The bill does not otherwise revise or expand the scope of optometrist prescribing authority.

At least ten other states, including Alaska, Arkansas, Arizona, Colorado, Georgia, Illinois, Kentucky, Louisiana, Oklahoma, and Utah have enacted similar legislation authorizing optometrists licensed in those states to continue prescribing pharmaceutical agents containing hydrocodone as they did prior to federal rescheduling.

Authorizes optometrists to continue prescribing medications containing hydrocodone.

SENATE, No. 2578

STATE OF NEW JERSEY

216th LEGISLATURE

INTRODUCED DECEMBER 1, 2014

Sponsored by:

Senator NIA H. GILL

District 34 (Essex and Passaic)

Senator JOSEPH F. VITALE

District 19 (Middlesex)

Assemblyman PATRICK J. DIEGNAN, JR.

District 18 (Middlesex)

Assemblyman SCOTT T. RUMANA

District 40 (Bergen, Essex, Morris and Passaic)

Assemblyman PAUL D. MORIARTY

District 4 (Camden and Gloucester)

Assemblyman THOMAS P. GIBLIN

District 34 (Essex and Passaic)

Assemblyman JACK M. CIATTARELLI

District 16 (Hunterdon, Mercer, Middlesex and Somerset)

Co-Sponsored by:

Senator Pennacchio and Assemblyman Benson

SYNOPSIS

Authorizes optometrists to continue prescribing medications containing hydrocodone.

CURRENT VERSION OF TEXT

As introduced.

(Sponsorship Updated As Of: 5/15/2015)

1	AN ACT concerning optometrist prescribing authority and amending
2	P.L.1991, c.385.
3	
4	BE IT ENACTED by the Senate and General Assembly of the State
5	of New Jersey:
6	
7	1. Section 9 of P.L.1991, c.385 (C.45:12-9.11) is amended to
8	read as follows:
9	9. a. Whenever in any law there is a requirement or duty with
10	respect to the prescription, administration or dispensing of any drug
11	which applies to any person authorized to prescribe that drug, the
12	same shall apply to an optometrist when prescribing, administering
13	or dispensing a pharmaceutical agent pursuant to R.S.45:12-1,
14	except that an optometrist shall not dispense a prescription as
15	provided for in R.S.45:12-1 in an amount exceeding a 72-hour
16	supply of that prescription unless the prescription is dispensed at no
17	charge to the patient. Subject to the provisions of P.L.1991, c.385
18	(C.45:12-9.8 et seq.), an optometrist authorized to prescribe,
19	administer, or dispense a pharmaceutical agent shall be permitted to
20	prescribe, administer, and dispense for the purpose of diagnosing
21	and treating deficiencies, deformities, diseases, or abnormalities of
22	the human eye and adnexae pharmaceutical agents classified as
23	Schedule III, IV, and V controlled dangerous substances and,
24	regardless of schedule, pharmaceutical agents containing
25	hydrocodone.
26	b. Notwithstanding the provisions of subsection a. of this
27	section, an optometrist may dispense a pharmaceutical agent, as
28	provided for in R.S.45:12-1, that is delivered to the eye through a
29	contact lens and may dispense such pharmaceutical agent at a
30	charge to the patient.
31	(cf: P.L.2010, c.12, s.2)
32	
33	2. This act shall take effect immediately.
34	
35	
36	STATEMENT
37	
38	This bill codifies current regulations concerning optometrist
39	prescribing authority, including permitting optometrists to
40	prescribe, administer, and dispense pharmaceutical agents
41	containing hydrocodone.
42	Under N.J.A.C.13:38-2.4, optometrists certified to prescribe
43	pharmaceutical agents are permitted to prescribe Schedule III, IV,

EXPLANATION – Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted in the law.

and V controlled dangerous substances. Pursuant to this authority,

optometrists have for many years prescribed products containing

44

S2578 GILL, VITALE

3

hydrocodone, formerly a Schedule III controlled dangerous
 substance, without incident.

Effective October 6, 2014, the Drug Enforcement Administration 3 4 in the U.S. Department of Justice rescheduled products containing 5 hydrocodone from Schedule III to Schedule II, meaning that 6 optometrists are no longer authorized to prescribe such products 7 under State law. This bill provides that, notwithstanding the federal 8 rescheduling of hydrocodone, optometrists will be permitted to 9 continue prescribing pharmaceutical agents containing hydrocodone 10 as they have historically done. The bill does not otherwise revise or 11 expand the scope of optometrist prescribing authority.

At least ten other states, including Alaska, Arkansas, Arizona, Colorado, Georgia, Illinois, Kentucky, Louisiana, Oklahoma, and Utah have enacted similar legislation authorizing optometrists licensed in those states to continue prescribing pharmaceutical agents containing hydrocodone as they did prior to federal rescheduling.

12

13

14

15

16

SENATE COMMERCE COMMITTEE

STATEMENT TO

SENATE, No. 2578

STATE OF NEW JERSEY

DATED: DECEMBER 8, 2014

The Senate Commerce Committee reports favorably Senate Bill No. 2578.

This bill codifies current regulations concerning optometrist prescribing authority, including permitting optometrists to prescribe, administer, and dispense pharmaceutical agents containing hydrocodone.

Under N.J.A.C.13:38-2.4, optometrists certified to prescribe pharmaceutical agents are permitted to prescribe Schedule III, IV, and V controlled dangerous substances. Pursuant to this authority, optometrists have for many years prescribed products containing hydrocodone, formerly a Schedule III controlled dangerous substance, without incident.

Effective October 6, 2014, the Drug Enforcement Administration in the U.S. Department of Justice rescheduled products containing hydrocodone from Schedule III to Schedule II, meaning that optometrists are no longer authorized to prescribe such products under State law. This bill provides that, notwithstanding the federal rescheduling of hydrocodone, optometrists will be permitted to continue prescribing pharmaceutical agents containing hydrocodone as they have historically done. The bill does not otherwise revise or expand the scope of optometrist prescribing authority.

At least ten other states, including Alaska, Arkansas, Arizona, Colorado, Georgia, Illinois, Kentucky, Louisiana, Oklahoma, and Utah have enacted similar legislation authorizing optometrists licensed in those states to continue prescribing pharmaceutical agents containing hydrocodone as they did prior to federal rescheduling.

ASSEMBLY REGULATED PROFESSIONS COMMITTEE

STATEMENT TO

SENATE, No. 2578

STATE OF NEW JERSEY

DATED: FEBRUARY 5, 2015

The Assembly Regulated Professions Committee reports favorably Senate Bill No. 2578.

This bill codifies current regulations concerning optometrist prescribing authority, including permitting optometrists to prescribe, administer, and dispense pharmaceutical agents containing hydrocodone.

Under N.J.A.C.13:38-2.4, optometrists certified to prescribe pharmaceutical agents are permitted to prescribe Schedule III, IV, and V controlled dangerous substances. Pursuant to this authority, optometrists have for many years prescribed products containing hydrocodone, formerly a Schedule III controlled dangerous substance, without incident.

Effective October 6, 2014, the Drug Enforcement Administration in the U.S. Department of Justice rescheduled products containing hydrocodone from Schedule III to Schedule II, meaning that optometrists are no longer authorized to prescribe such products under State law. This bill provides that, notwithstanding the federal rescheduling of hydrocodone, optometrists will be permitted to continue prescribing pharmaceutical agents containing hydrocodone as they have historically done. The bill does not otherwise revise or expand the scope of optometrist prescribing authority.

At least ten other states, including Alaska, Arkansas, Arizona, Colorado, Georgia, Illinois, Kentucky, Louisiana, Oklahoma, and Utah have enacted similar legislation authorizing optometrists licensed in those states to continue prescribing pharmaceutical agents containing hydrocodone as they did prior to federal rescheduling.

This bill is identical to Assembly Bill No. 3922, which was also reported by the committee today.

ASSEMBLY, No. 3922

STATE OF NEW JERSEY

216th LEGISLATURE

INTRODUCED DECEMBER 4, 2014

Sponsored by:

Assemblyman PATRICK J. DIEGNAN, JR.

District 18 (Middlesex)

Assemblyman SCOTT T. RUMANA

District 40 (Bergen, Essex, Morris and Passaic)

Assemblyman PAUL D. MORIARTY

District 4 (Camden and Gloucester)

Assemblyman THOMAS P. GIBLIN

District 34 (Essex and Passaic)

Assemblyman JACK M. CIATTARELLI

District 16 (Hunterdon, Mercer, Middlesex and Somerset)

Co-Sponsored by:

Assemblyman Benson

SYNOPSIS

Authorizes optometrists to continue prescribing medications containing hydrocodone.

CURRENT VERSION OF TEXT

As introduced.



(Sponsorship Updated As Of: 5/15/2015)

1 2	AN ACT concerning optometrist prescribing authority and amending P.L.1991, c.385.
3	1.L.1771, C.363.
4	BE IT ENACTED by the Senate and General Assembly of the State
5	of New Jersey:
6	of them sersey.
7	1. Section 9 of P.L.1991, c.385 (C.45:12-9.11) is amended to
8	read as follows:
9	9. a. Whenever in any law there is a requirement or duty with
10	respect to the prescription, administration or dispensing of any drug
11	which applies to any person authorized to prescribe that drug, the
12	same shall apply to an optometrist when prescribing, administering
13	or dispensing a pharmaceutical agent pursuant to R.S.45:12-1,
14	except that an optometrist shall not dispense a prescription as
15	provided for in R.S.45:12-1 in an amount exceeding a 72-hour
16	supply of that prescription unless the prescription is dispensed at no
17	charge to the patient. Subject to the provisions of P.L.1991, c.385
18	(C.45:12-9.8 et seq.), an optometrist authorized to prescribe,
19	administer, or dispense a pharmaceutical agent shall be permitted to
20	prescribe, administer, and dispense for the purpose of diagnosing
21	and treating deficiencies, deformities, diseases, or abnormalities of
22	the human eye and adnexae pharmaceutical agents classified as
23	Schedule III, IV, and V controlled dangerous substances and,
24	regardless of schedule, pharmaceutical agents containing
25	hydrocodone.
26	b. Notwithstanding the provisions of subsection a. of this
27	section, an optometrist may dispense a pharmaceutical agent, as
28	provided for in R.S.45:12-1, that is delivered to the eye through a
29	contact lens and may dispense such pharmaceutical agent at a
30	charge to the patient.
31	(cf: P.L.2010, c.12, s.2)
32	
33	2. This act shall take effect immediately.
34	
35	
36	STATEMENT
37	
38	This bill codifies current regulations concerning optometrist
39	prescribing authority, including permitting optometrists to
40	prescribe, administer, and dispense pharmaceutical agents
41	containing hydrocodone.
42	Under N.J.A.C.13:38-2.4, optometrists certified to prescribe
43	pharmaceutical agents are permitted to prescribe Schedule III, IV,

EXPLANATION – Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted in the law.

and V controlled dangerous substances. Pursuant to this authority,

optometrists have for many years prescribed products containing

A3922 DIEGNAN, RUMANA

3

hydrocodone, formerly a Schedule III controlled dangerous
 substance, without incident.

Effective October 6, 2014, the Drug Enforcement Administration 3 4 in the U.S. Department of Justice rescheduled products containing 5 hydrocodone from Schedule III to Schedule II, meaning that 6 optometrists are no longer authorized to prescribe such products 7 under State law. This bill provides that, notwithstanding the federal 8 rescheduling of hydrocodone, optometrists will be permitted to 9 continue prescribing pharmaceutical agents containing hydrocodone 10 as they have historically done. The bill does not otherwise revise or 11 expand the scope of optometrist prescribing authority.

12

13

14

15

16

17

At least ten other states, including Alaska, Arkansas, Arizona, Colorado, Georgia, Illinois, Kentucky, Louisiana, Oklahoma, and Utah have enacted similar legislation authorizing optometrists licensed in those states to continue prescribing pharmaceutical agents containing hydrocodone as they did prior to federal rescheduling.

ASSEMBLY REGULATED PROFESSIONS COMMITTEE

STATEMENT TO

ASSEMBLY, No. 3922

STATE OF NEW JERSEY

DATED: FEBRUARY 5, 2015

The Assembly Regulated Professions Committee reports favorably Assembly Bill No. 3922.

This bill codifies current regulations concerning optometrist prescribing authority, including permitting optometrists to prescribe, administer, and dispense pharmaceutical agents containing hydrocodone.

Under N.J.A.C.13:38-2.4, optometrists certified to prescribe pharmaceutical agents are permitted to prescribe Schedule III, IV, and V controlled dangerous substances. Pursuant to this authority, optometrists have for many years prescribed products containing hydrocodone, formerly a Schedule III controlled dangerous substance, without incident.

Effective October 6, 2014, the Drug Enforcement Administration in the U.S. Department of Justice rescheduled products containing hydrocodone from Schedule III to Schedule II, meaning that optometrists are no longer authorized to prescribe such products under State law. This bill provides that, notwithstanding the federal rescheduling of hydrocodone, optometrists will be permitted to continue prescribing pharmaceutical agents containing hydrocodone as they have historically done. The bill does not otherwise revise or expand the scope of optometrist prescribing authority.

At least ten other states, including Alaska, Arkansas, Arizona, Colorado, Georgia, Illinois, Kentucky, Louisiana, Oklahoma, and Utah have enacted similar legislation authorizing optometrists licensed in those states to continue prescribing pharmaceutical agents containing hydrocodone as they did prior to federal rescheduling.

This bill is identical to Senate Bill No. 2578, which was also reported by the committee today.